These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19247295)

  • 21. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 22. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geron's quixotic fate.
    Scott C; Huggett B
    Nat Biotechnol; 2012 Jun; 30(6):497. PubMed ID: 22678383
    [No Abstract]   [Full Text] [Related]  

  • 24. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 25. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 26. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
    Sherrid P
    US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
    [No Abstract]   [Full Text] [Related]  

  • 27. Patent fight sparks biological warfare in the drug industry.
    Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
    [No Abstract]   [Full Text] [Related]  

  • 28. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 29. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 30. Congress works to permit 'biosimilar' drugs very soon.
    Carroll J
    Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559
    [No Abstract]   [Full Text] [Related]  

  • 31. Meeting in the middle.
    Nature; 2007 Jun; 447(7145):629. PubMed ID: 17554281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cheaper clinical trials: the real solution to the biologic industry's Gordian knot.
    Montas A
    Am J Law Med; 2011; 37(1):172-93. PubMed ID: 21614998
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharma swept up in biogenerics gold rush.
    Ratner M
    Nat Biotechnol; 2009 Apr; 27(4):299-301. PubMed ID: 19352348
    [No Abstract]   [Full Text] [Related]  

  • 34. An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?
    Minssen T; Kesselheim AS; Darrow JJ
    Nat Biotechnol; 2019 Jan; 37(1):21-22. PubMed ID: 30605154
    [No Abstract]   [Full Text] [Related]  

  • 35. Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall.
    Dorey E
    Nat Biotechnol; 2010 Nov; 28(11):1137-8. PubMed ID: 21057465
    [No Abstract]   [Full Text] [Related]  

  • 36. $3m deal launches major hunt for drug leads in Brazil.
    Bonalume Neto R; Dickson D
    Nature; 1999 Jul; 400(6742):302. PubMed ID: 10432100
    [No Abstract]   [Full Text] [Related]  

  • 37. Can cells be generic?
    Gibbs WW
    Sci Am; 2003 Dec; 289(6):48. PubMed ID: 14631730
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech patents-business as usual?
    Lawrence S
    Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
    [No Abstract]   [Full Text] [Related]  

  • 39. Market exclusivity for biologics.
    Wheadon DE
    N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
    [No Abstract]   [Full Text] [Related]  

  • 40. Patent crunch pending.
    Wadman M
    Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.